Nedaplatin: a new platinum for squamous lung cancer?

Abstract

The place of platinum doublets in first-line chemotherapy for advanced non-small-cell lung cancer in the absence of a targetable driver mutation is now well established. 1 Schiller JH Harrington D Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346: 92-98 Crossref PubMed Scopus (4802) Google Scholar With the exception of pemetrexed for non-squamous non-small-cell lung cancer, no trials have shown a clear advantage for any particular third generation drug to pair with platinum, 2 Scagliotti GV Parikh P von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-3551 Crossref PubMed Scopus (2884) Google Scholar and clinicians choose from a range of equivalent drugs. By contrast, cisplatin has remained the platinum-based drug of choice in patients with a good performance status. 3 Hotta K Matsuo K Ueoka H Kiura K Tabata M Tanimoto M Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22: 3852-3859 Crossref PubMed Scopus (339) Google Scholar , 4 Ardizzoni A Boni L Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99: 847-857 Crossref PubMed Scopus (559) Google Scholar , 5 Jiang J Liang X Zhou X Huang R Chu Z A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2007; 57: 348-358 Summary Full Text Full Text PDF PubMed Scopus (92) Google Scholar , 6 D'Addario G Pintilie M Leighl NB Feld R Cerny T Shepherd FA Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005; 23: 2926-2936 Crossref PubMed Scopus (327) Google Scholar The combination of cisplatin with docetaxel is well supported by randomised studies, and is a very widely used standard of care in Japan for squamous non-small-cell lung cancer. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trialOverall survival was significantly longer with nedaplatin plus docetaxel than with cisplatin plus docetaxel, and the regimens had different safety profiles. Nedaplatin plus docetaxel could be a new treatment option for advanced or relapsed squamous cell lung cancer. Full-Text PDF